期刊
CELL REPORTS
卷 20, 期 6, 页码 1269-1277出版社
CELL PRESS
DOI: 10.1016/j.celrep.2017.07.031
关键词
-
类别
资金
- Department of Defense (DOD) [W81XWH-10- 1-0254]
- National Multiple Sclerosis Society (NMSS) [RG 5138A1/1T]
- National Multiple Sclerosis Society [RG 5138A1/1T]
- BioFire
- Check-Points
- Curetis
- 3M
- Merck
- Roche
- Qvella
- Diaxonhit
- ASM
- IDSA
- NIH [GM092993, NS048357, NS073684]
- NIH CTSA [RR024150, TR000135]
- Novartis Pharmaceuticals
- European Regional Development Fund (FNUSA-ICRC) [CZ.1.05/1.1.00/02.0123]
- Applebaum
- Hilton
- Peterson
- McNeilus Foundations
The human gut is colonized by a large number of microorganisms (similar to 10(13) bacteria) that support various physiologic functions. A perturbation in the healthy gut microbiome might lead to the development of inflammatory diseases, such as multiple sclerosis (MS). Therefore, gut commensals might provide promising therapeutic options for treating MS and other diseases. We report the identification of human gut-derived commensal bacteria, Prevotella histicola, which can suppress experimental autoimmune encephalomyelitis (EAE) in a human leukocyte antigen (HLA) class II transgenic mouse model. P. histicola suppresses disease through the modulation of systemic immune responses. P. histicola challenge led to a decrease in pro-inflammatory Th1 and Th17 cells and an increase in the frequencies of CD4(+) FoxP3(+) regulatory T cells, tolerogenic dendritic cells, and suppressive macrophages. Our study provides evidence that the administration of gut commensals may regulate a systemic immune response and may, therefore, have a possible role in treatment strategies for MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据